The Zika virus (ZIKV) was first isolated from a rhesus macaque in the Zika forest of Uganda in 1947. Isolated cases were reported until 2007, when the first major outbreaks of Zika infection were reported from the Island of Yap in Micronesia and from French Polynesia in 2013. In 2015, ZIKV started to circulate in Latin America, and in 2016, ZIKV was considered by WHO to be a Public Health Emergency of International Concern due to cases of Congenital Zika Syndrome (CZS), a ZIKV-associated complication never observed before. After a peak of cases in 2016, the infection incidence dropped dramatically but still causes concern because of the associated microcephaly cases, especially in regions where the dengue virus (DENV) is endemic and co-circulates with ZIKV. A vaccine could be an important tool to mitigate CZS in endemic countries. However, the immunological relationship between ZIKV and other flaviviruses, especially DENV, and the low numbers of ZIKV infections are potential challenges for developing and testing a vaccine against ZIKV. Here, we discuss ZIKV vaccine development with the perspective of the immunological concerns implicated by DENV-ZIKV cross-reactivity and the use of a controlled human infection model (CHIM) as a tool to accelerate vaccine development.
Human leukocyte antigen B*27 (HLA-B*27) is a major risk factor for autoimmune diseases such as axial spondyloarthritis (axSpA), acute anterior uveitis (AAU), and psoriatic arthritis (PsA). HLA-B*27 presents bacterial and self-antigens to disease-associated CD8+ T cells, however, how this leads to a pathogenic IL-17-mediated disease remains unclear. We performed mutational experiments in an established disease-associated TCR and demonstrated that the pathogenic motif encompasses a wider range of TCR sequences than previously appreciated. We next leveraged computational pairing of alpha/beta TCR sequencing (TCR-seq) to demonstrate that the broadened pathogenic motif distinguishes axSpA and AAU patients from healthy controls. Paired single-cell RNA sequencing and single-cell TCR sequencing datasets demonstrated that the pathogenic cells have a distinct transcriptional signature. We find a coupling of pathogenic TCRs to this transcriptional signature in public datasets from axSpA and PsA joint fluid and AAU ocular fluid. Finally, we detect the pathogenic CD8+ T cells in the gut and demonstrate that they express a Type 17 program. Our findings suggest that HLA-B*27+ axSpA, AAU, and PsA are initiated by HLA-B*27-restricted pathogenic CD8+ T cells that undergo Type 17 differentiation in response to intestinal antigens. One Sentence Summary: Multiple HLA-B*27-associated autoimmune diseases share the same pathogenic CD8+ T cells with Type 17 gene expression and cytokine production.
19 February 2026 in Clinical Immunology Communications
We investigated discordant SARS-CoV-2 infection outcomes among household contacts. 95 recently-exposed household contacts were recruited from June 2020 to February 2023 in a prospective study of “discordant pairs”, where one individual experienced documented SARS-CoV-2 infection while another close contact consistently tested negative despite shared living arrangements. We collected pre- and post-infection samples and analyzed both SARS-CoV-2 and common cold coronavirus (CCC)-specific T cell responses, as well as spike RBD neutralizing and nucleocapsid-binding antibody titers. Antibody and cellular immune responses did not identify a single predominant mechanism explaining discordant outcomes. Instead, we observed distinct immunological patterns that could be associated with protection from infection across different household contacts. In ~40% of cases, uninfected individuals showed pre-existing immunity to non-spike antigens and CCC sequences. Moreover, 30% of uninfected individuals displayed evidence suggestive of abortive infections, characterized by increased T responses without detectable changes in antibody levels. The remaining cases showed no clear changes in immunological patterns. Multiple immunity-associated factors operate in household settings for SARS-CoV-2-exposed individuals who do not develop overt infection, including both pre-existing immunity and abortive or transient infections. Although causality cannot be established without additional functional assays, this diversity of protective immune responses might help explain why some individuals remain uninfected despite close contact with SARS-CoV-2-positive household members.
14 November 2023 in Cellular & Molecular Immunology